Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02458469 · ClinicalTrials.gov registry record · Phase 2
Role of Enhancing Serotonin Receptors Activity for Sleep Apnea Treatment in Patients With SCI
A Phase 2 study, sponsored by VA Office of Research and Development.
- Completed
- Registry status
- Phase 2
- Development phase
- 15
- Enrollment target
NCT02458469: Completed Phase 2 study, sponsored by VA Office of Research and Development.
NCT02458469 is a Phase 2 study that has completed, run by VA Office of Research and Development. The registered enrollment target is 15 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02458469, a Phase 2 study, has completed, sponsored by VA Office of Research and Development.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 15 participants
- Enrollment target
Study Summary
The purpose of this study is to look at the effect of exciting using drugs to target a specific pathway in the body, that relies on a natural chemical the body produces called 'serotonin', in patients with spinal cord injury (SCI) during sleep. During this part of the study participants will be asked to take buspirone (Buspar) (15-50mg per day), trazodone (100mg per day) and a placebo in a random fashion, each for a 2 week period (drug period) of time followed by two weeks without drugs (washout period). The drugs will not be taken all at the same time, but each will be taken separately for two weeks followed by a night study to look at the effect the medication/placebo pill has on the way the body responds during sleep.
Interventions
- DRUG Placebo
- DRUG Trazodone
- DRUG Buspirone
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 15 participants |
| Start Date | 2015-05-14 |
| Est. Completion | 2019-04-12 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02458469
The ClinicalTrials.gov registry entry for NCT02458469 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 15 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is VA Office of Research and Development, which has 1,668 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT02458469 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02458469 about?
NCT02458469 is a clinical study titled "Role of Enhancing Serotonin Receptors Activity for Sleep Apnea Treatment in Patients With SCI". The purpose of this study is to look at the effect of exciting using drugs to target a specific pathway in the body, that relies on a natural chemical the body produces called 'serotonin', in patients with spinal cord injury (SCI) during sleep. During this part of the study participants will be aske...
What is the current status of trial NCT02458469?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 15 participants. The study started on 2015-05-14. Estimated completion is 2019-04-12.
What interventions are being tested in trial NCT02458469?
The interventions under investigation include: Placebo (DRUG), Trazodone (DRUG), Buspirone (DRUG).
Who is sponsoring clinical trial NCT02458469?
This trial is sponsored by VA Office of Research and Development, which has 1,668 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.